Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now. On August 7, William Blair analyst ...

H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The ...

Genmab and AbbVie are taking key steps toward moving their blood cancer drug Epkinly into earlier lines of treatment in follicular lymphoma (FL). | Genmab and AbbVie have presented new data that could ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Genmab (Otc) (($GMAB)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Phase 1b/2 Open-Label ...

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in ...

Genmab AS (GMAB) reports a 19% revenue increase and a 56% rise in operating profit, showcasing strong financial performance ...

The promising results, along with a separate FDA decision, could signal a major expansion of the use of the two companies' ...

Genmab shares were 6% higher, at $22.72 a share, after the company reported positive results of a Phase 3 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide in ...

Danish biotech Genmab (Nasdaq: GMAB) posted second-quarter revenue of $925 million, up 19% from a year earlier, driven by ...

Genmab Announces Financial Results for the First Half of 2025August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025HighlightsEpcoritamab advancing to earlier lines ...